2001 Clinical Trials Patients Treatment 
Cannabis Law Report
MARCH 23, 2022
Psychedelic medicine could provide much needed treatment options for some mental health and neurological disorders in the near future. However, our drug laws impede research and deny patients access to these highly effective medicines. There are a number of differences between PAP and current treatment approaches.
The Cannigma
MAY 19, 2021
Japan does not have a medical cannabis program and does not allow the use of cannabis for patients seeking to treat a medical condition. In 2019, Japan approved clinical trials for Epidiolox — a cannabis derived medicine used to treat severe forms of childhood epilepsy such as Dravet and Lennox-Gastaut syndromes. Shutterstock).
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
CannaTech
SEPTEMBER 16, 2018
Canada has been at the forefront of shaping much of the rhetoric surrounding cannabis since 2001. Doctors have remained integral parts of a patient’s cannabis journey through what is known as the Access to Cannabis for Medical Purposes Regulation (ACMPR) act. The Need for Cannabis Education Tailored to Patient and Doctor.
Cannabis Law Report
MARCH 1, 2019
Natalie has worked with private hospitals and clinics in relation to medical malpractice claims, and assisted on cases involving medical devices product liability and clinical trials. But doctors and patients are not only facing administrative or prescribing hurdles – there’s also the cost. Legalisation.
CannaMD
AUGUST 26, 2020
Current Cocaine Treatments. As researchers point out: There is no gold standard pharmacological treatment for dependence on cocaine. Although several drugs have been investigated, there is no strong or consistent evidence indicating any of these drugs for the treatment of cocaine use disorder. mice/rats).
Otherside Farms
JANUARY 23, 2019
Differential effects of repeated low dose treatment with the cannabinoid agonist WIN 55,212-2 in experimental models of bone cancer pain and neuropathic pain. cancer cells (full – 2001). Inhibition of Glioma Growth in Vivo by Selective Activation of the CB2 Cannabinoid Receptor1 (full – 2001). full – 2001).
The Cannigma
JANUARY 13, 2023
The fact that migraine is now ranked as the second leading cause of years lived with disability illustrates the magnitude of the negative impact of the disease to patients and their ability to function normally. A 2019 retrospective review of 316 patients found that medical cannabis improved the experience of 88.3% headaches per month.
Expert insights. Personalized for you.
52 
Let's personalize your content